GSK’s Share Price Offers Attractive Risk Reward, Jefferies Says
0836 GMT – GSK is expected to guide for at least low single-digit EPS growth for 2024 and settle the Zantac litigation case within the coming months, Jefferies analysts write in a research note as they raise their rating on the stock to buy from hold. They estimate that the pharmaceutical company…
#gsk #eps #zantac #jefferies